Jazz Pharmaceuticals (JAZZ) Intangibles (2010 - 2026)
Jazz Pharmaceuticals' quarterly Intangibles came in at $4.2 billion in Q1 2026, down 10.9% year-on-year from $4.7 billion in Q1 2025, and down 5.1% quarter-over-quarter from $4.4 billion in Q4 2025.
Jazz Pharmaceuticals has reported Intangibles for 17 years, with the latest figure at $4.2 billion in Q1 2026.
- For the quarter ending Q1 2026, Intangibles fell 10.9% year-over-year to $4.2 billion; the trailing twelve-month figure through Mar 2026 stood at $4.2 billion (down 10.9% YoY), and the FY2025 full-year result was $4.4 billion, down 6.86% from the prior year.
- Intangibles for Q1 2026 stood at $4.2 billion, down from $4.4 billion in the prior quarter.
- The five-year high for Intangibles was $6.8 billion in Q1 2022, with the low at $752.5 million in Q4 2023.
- Average Intangibles over 5 years is $5.0 billion, with a median of $5.1 billion recorded in 2024.
- Year-over-year, Intangibles jumped 556939.4% in 2022 and sank 87.01% in 2023.
- Tracing JAZZ's Intangibles over 5 years: stood at $5.8 billion in 2022, then slumped by 87.01% to $752.5 million in 2023, then soared by 531.99% to $4.8 billion in 2024, then dropped by 6.86% to $4.4 billion in 2025, then declined by 5.1% to $4.2 billion in 2026.
- The last three Intangibles figures came in at $4.2 billion (Q1 2026), $4.4 billion (Q4 2025), and $4.6 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 4.41 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 11,640.44 |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 30.30 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 418.50 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.29 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Jazz Pharmaceuticals | 14.35 Bn | 12.51 Bn | 934.80 Mn | 4.20 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.20 Bn |
| Dec 31, 2025 | 4.43 Bn |
| Sep 30, 2025 | 4.57 Bn |
| Jun 30, 2025 | 4.77 Bn |
| Mar 31, 2025 | 4.72 Bn |
| Dec 31, 2024 | 4.76 Bn |
| Sep 30, 2024 | 5.14 Bn |
| Jun 30, 2024 | 5.08 Bn |
| Mar 31, 2024 | 5.24 Bn |
| Dec 31, 2023 | 752.50 Mn |
| Sep 30, 2023 | 5.42 Bn |
| Jun 30, 2023 | 5.71 Bn |
| Mar 31, 2023 | 5.76 Bn |
| Dec 31, 2022 | 5.79 Bn |
| Sep 30, 2022 | 5.57 Bn |
| Jun 30, 2022 | 6.24 Bn |
| Mar 31, 2022 | 6.78 Bn |
| Dec 31, 2021 | 7.15 Bn |
| Sep 30, 2021 | 1.00 Mn |
| Jun 30, 2021 | 7.59 Bn |
| Mar 31, 2021 | 2.11 Bn |
| Dec 31, 2020 | 2.20 Bn |
| Sep 30, 2020 | 2.24 Bn |
| Jun 30, 2020 | 100.00 Mn |
| Mar 31, 2020 | 2.24 Bn |
| Dec 31, 2019 | 2.44 Bn |
| Sep 30, 2019 | 2.59 Bn |
| Jun 30, 2019 | 2.69 Bn |
| Mar 31, 2019 | 2.68 Bn |
| Dec 31, 2018 | 2.73 Bn |
| Sep 30, 2018 | 2.79 Bn |
| Jun 30, 2018 | 2.84 Bn |
| Mar 31, 2018 | 2.95 Bn |
| Dec 31, 2017 | 2.98 Bn |
| Sep 30, 2017 | 3.02 Bn |
| Jun 30, 2017 | 3.03 Bn |
| Mar 31, 2017 | 3.00 Bn |
| Dec 31, 2016 | 3.01 Bn |
| Sep 30, 2016 | 3.11 Bn |
| Jun 30, 2016 | 1.30 Bn |
| Mar 31, 2016 | 1.35 Bn |
| Dec 31, 2015 | 1.19 Bn |
| Sep 30, 2015 | 1.27 Bn |
| Jun 30, 2015 | 1.28 Bn |
| Mar 31, 2015 | 1.28 Bn |
| Dec 31, 2014 | 1.44 Bn |
| Sep 30, 2014 | 1.55 Bn |
| Jun 30, 2014 | 1.68 Bn |
| Mar 31, 2014 | 1.76 Bn |
| Dec 31, 2013 | 812.40 Mn |
| Sep 30, 2013 | 823.72 Mn |
| Jun 30, 2013 | 822.98 Mn |
| Mar 31, 2013 | 835.00 Mn |
| Dec 31, 2012 | 869.95 Mn |
| Sep 30, 2012 | 876.96 Mn |
| Jun 30, 2012 | 994.04 Mn |
| Mar 31, 2012 | 326.07 Mn |
| Dec 31, 2011 | 14.59 Mn |
| Sep 30, 2011 | 16.45 Mn |
| Jun 30, 2011 | 18.31 Mn |
| Dec 31, 2010 | 22.03 Mn |